A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications

Publisher： Govi-Verlag

ISSN： 0031-7144

Source： Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol.69, Iss.10, 2014-10, pp. : 747-751

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy

By  

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 3, 2011-01 ,pp. : 373-385

Bentham Science Publishers

Access to resources Recommend Favorite

Aldose Reductase in Diabetic Microvascular Complications

By  

Current Drug Targets, Vol. 6, Iss. 4, 2005-06 ,pp. : 475-486

Bentham Science Publishers

Access to resources Recommend Favorite

Aldose reductase inhibitors: therapeutic implications for diabetic complications

By Oates P.J.   Mylari B.L.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 12, 1999-12 ,pp. : 2095-2119

Informa Healthcare

Access to resources Recommend Favorite

Genetic Analysis of Aldose Reductase in Diabetic Complications

By  

Current Medicinal Chemistry, Vol. 10, Iss. 15, 2003-08 ,pp. : 1375-1387

Bentham Science Publishers

Access to resources Recommend Favorite

Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats

By Nakayama K.   Murakami N.   Ohta M.   Kato K.   Ida K.   Mizota M.   Miwa I.   Okuda J.  

European Journal of Pharmacology, Vol. 276, Iss. 1, 1995-03 ,pp. : 77-83

Elsevier

Access to resources Recommend Favorite